FLASCO OncoPod

Join FLASCO OncoPod for a special conversation with Dr. Jani and Dr. Rosas as they highlight the South Florida Fellows Hematology Oncology (SOFLOH) initiative and the upcoming FLASCO Fellows & Residents Training Program.

In this episode, our guests discuss the importance of mentorship, professional development, and meaningful connections for the next generation of hematology and oncology professionals. Learn more about SOFLOH's mission to support fellows and residents, the opportunities available through FLASCO, and what attendees can look forward to at this year's training program.

Whether you're a current fellow, resident, or physician passionate about supporting the future of oncology, this episode offers a closer look at the people and programs helping shape the next generation of cancer care.

Selecting an effective treatment is only the beginning of managing metastatic triple-negative breast cancer (mTNBC). In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk examine the practical challenges of delivering and sustaining therapy, from treatment initiation through disease progression. Using a longitudinal patient case and findings from a FLASCO clinician survey, faculty discuss toxicity prevention and management, dose modifications, and the clinical considerations surrounding antibody-drug conjugate (ADC) therapy.

The conversation explores treatment scheduling, insurance authorization, financial barriers, and strategies to support treatment continuity. Faculty also address rebiopsy, biomarker reassessment, therapeutic sequencing, and the importance of timely clinical trial referrals to help optimize care throughout the patient's treatment journey.

This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.

How should clinicians approach metastatic triple-negative breast cancer (mTNBC) when a patient's treatment history does not align with the populations studied in clinical trials? In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk explore the challenges of managing patients who experience recurrence following neoadjuvant immunotherapy and chemotherapy.

Through case-based discussion and insights from a FLASCO clinician survey, faculty examine the significance of treatment-free intervals, prior immunotherapy exposure, germline BRCA mutations, and the evolving first-line treatment landscape. The conversation also addresses the limitations of available clinical evidence, considerations for immunotherapy rechallenge, and individualized treatment strategies for patients with comorbidities, reduced performance status, or preferences that may limit therapeutic options.

This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.

Treatment decisions in metastatic triple-negative breast cancer (mTNBC) are becoming increasingly complex as new therapeutic options reshape the first-line landscape. In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk examine the clinical decisions surrounding PD-L1 expression, germline BRCA mutations, and the evolving role of antibody-drug conjugates (ADCs). Drawing on insights from a FLASCO clinician survey, the discussion explores biomarker testing, treatment selection while results are pending, and the implications of recent first-line sacituzumab govitecan approvals.

Faculty review findings from the ASCENT-03 and ASCENT-04 trials, address areas of clinical uncertainty, and discuss how emerging evidence influences shared decision-making when overall survival data remain immature.

This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.

In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing cancer care beyond the clinic. Drawing on years of experience working alongside healthcare organizations and oncology professionals, Drew discusses how trusted clinician voices can influence public policy, improve patient access to care, and strengthen public confidence in the healthcare system.

Listeners will gain practical insights into communicating complex healthcare issues with clarity, combining patient stories with evidence-based data, and engaging policymakers in meaningful ways that drive positive change. Whether through community outreach, media engagement, or legislative advocacy, this episode highlights how every oncology professional can help shape the future of cancer care through authentic, patient-centered communication.

Sachs Health INFLUENCE INDEX: https://sachsmedia.com/wp-content/uploads/2026/05/SachsHEALTH-Influence-Index-2026.pdf

Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver disease and cancer management. In this episode of the FLASCO OncoPod, Dr. Beau Bosko Toskich, MD, FSIR, Professor of Radiology, Medical Oncology, and Radiation Oncology and Director of Interventional Oncology at Mayo Clinic Comprehensive Cancer Center, provides a comprehensive overview of the modern HCC treatment landscape.

Dr. Toskich discusses the changing epidemiology of hepatocellular carcinoma, emphasizing the growing impact of metabolic-associated liver disease, the importance of early detection and surveillance, and opportunities for disease prevention. He explores how multidisciplinary collaboration—including hepatology, surgery, interventional radiology, medical oncology, and radiation oncology—has transformed patient care, while highlighting the expanding role of locoregional therapies, immunotherapy, transplant evaluation, and emerging combination treatment strategies. Listeners will gain practical insights into patient selection, downstaging approaches, and the latest advances that are reshaping outcomes for patients with HCC.

Whether you routinely manage liver cancer or simply want to stay current on one of oncology's fastest-evolving disease states, this episode offers valuable clinical perspectives on delivering personalized, multidisciplinary care for patients with hepatocellular carcinoma.

In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the evolving role of community oncology and how today's practices are delivering academic-level cancer care closer to home.

Together, they explore how community oncology has transformed over the past decade, highlighting advances in precision medicine, immunotherapy, clinical research, and innovative care models. The conversation examines how large practice networks maintain consistent, high-quality care while expanding access to cutting-edge therapies and clinical trials for patients across diverse communities.

From scaling innovation across a statewide network to bringing academic-level expertise closer to home, this episode offers valuable insights into the future of oncology care and the increasingly vital role community oncology plays in advancing cancer treatment, research, and patient outcomes.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

In part 4, the panel examines the real-world barriers that continue to affect IHC testing, including variability in reflex testing, pathology workflows, tissue stewardship, and reporting consistency. Experts share practical strategies for improving communication between oncologists and pathologists, streamlining testing protocols, and ensuring patients receive timely, comprehensive biomarker evaluation. Looking ahead, the discussion explores how artificial intelligence, digital pathology, electronic medical record integration, and automated clinical trial matching may transform precision oncology while reinforcing that multidisciplinary collaboration remains essential to delivering high-quality, personalized cancer care. The episode concludes with key takeaways clinicians can implement to strengthen biomarker-driven decision-making in their own practices.

This podcast is being sponsored by Daiichi Sankyo.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

The panel discusses how expanding biomarker indications are changing when and how testing is performed, from first-line diagnosis through disease progression. Experts explore the growing clinical importance of HER2-low and HER2-ultralow expression in breast cancer, the role of comprehensive biomarker testing in gynecologic malignancies, and how IHC and next-generation sequencing work together to guide personalized treatment strategies in thoracic oncology. The conversation also highlights the importance of standardized pathology reporting, multidisciplinary collaboration, and balancing timely treatment with the need for complete biomarker results to ensure patients receive the most appropriate targeted therapies.

This podcast is being sponsored by Daiichi Sankyo.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

In part 2, the panel explores why routine biomarker testing is becoming an essential part of cancer care, highlighting how markers such as mismatch repair (MMR), HER2, PD-L1, and Claudin 18.2 are helping clinicians personalize treatment strategies and improve patient outcomes. Through real-world clinical examples, the discussion examines the value of reflex testing, when repeat testing may be appropriate, and how close collaboration between oncologists, pathologists, and multidisciplinary care teams helps ensure patients receive timely, biomarker-driven treatment. The conversation also addresses practical workflow considerations, including pathology communication, turnaround times, and strategies for integrating evolving testing standards into everyday clinical practice.

This podcast is being sponsored by Daiichi Sankyo.